The role of PD-1/PD-L1 checkpoint in arsenic lung tumorigenesis

被引:7
|
作者
Xu, Wenhua [1 ,2 ]
Cui, Jiajun [1 ,3 ]
Wu, Linqing [1 ,4 ]
He, Caigu [1 ,5 ]
Chen, Gang [1 ]
机构
[1] Univ Kentucky, Dept Pharmacol & Nutr Sci, Coll Med, MN306,800 Rose St, Lexington, KY 40536 USA
[2] Univ Sci & Technol China, Dept Neurol, Affiliated Hosp 1, Hefei 230001, Anhui, Peoples R China
[3] Yichun Univ, Coll Med, Dept Biochem, Yichun 336000, Jiangxi, Peoples R China
[4] Fujian Med Univ, Sch Basic Med Sci, Dept Immunol, Fuzhou 350003, Fujian, Peoples R China
[5] Fujian Univ Tradit Chinese Med, Dept Histol & Embryol, Fuzhou 361000, Fujian, Peoples R China
关键词
Arsenic; Lung; Tumor; T cell; PD-1; PD-L1; REGULATORY T-CELLS; CANCER; CD8(+); EXHAUSTION; PROLIFERATION; IMMUNOTHERAPY; LYMPHOCYTES; EXPRESSION; MODELS; PD-L1;
D O I
10.1016/j.taap.2021.115633
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic exposure to environmental arsenic promotes lung cancer. Emerging evidence indicates that compromised host immunity, particularly T cell anti-tumor immunity, may play a critical role in cancer development. However, there is a knowledge gap in terms of the effects of arsenic exposure on T cell anti-tumor immunity and how that may contribute to arsenic lung carcinogenicity. Immunosuppression has been known as a risk factor for many types of cancer, including lung cancer. The development of cancer indicates the success of immunosuppression and escape of cancer cells from host anti-tumor immunity in which T cells are the major component. The anti-tumor immunity is mainly executed by CD8 cytotoxic T cells through their anti-tumor effector function, which can be regulated by immune checkpoint pathways. Some inhibitory receptors on the T cell membrane and their ligands form these pathways, among which programmed death-1 (PD-1), a T cell inhibitory receptor, and its ligand, programmed death-ligand 1 (PD-L1), are best characterized. A/J mice are naturally sensitive to pulmonary carcinogens, prone to develop spontaneous lung tumors later in life and have been frequently used as an animal model for lung tumorigenesis research. Chronic arsenic administration through drinking water has been shown to enhance tumor formation in the lungs of A/J mice. In the current study, using this mouse model we want to determine whether PD-1/PD-L1 plays a role in arsenic-enhanced lung tumorigenesis. The results showed that prolonged arsenic exposure up-regulated PD-1/PD-L1, increased regulatory T cells (Tregs), decreased CD8/ Treg ratio, inhibited T cell antitumor function in the lungs and enhanced lung tumor formation, while inhibition of PD-1/PD-L1 restored CD8/Treg ratio and T cell anti-tumor effector function, and mitigated arsenic-enhanced lung tumorigenesis. In addition, inhibition of PD-1/PD-L1 could be a potential preventive strategy to mitigate the tumorigenic action of chronic arsenic exposure.
引用
收藏
页数:8
相关论文
共 50 条
  • [11] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Bai, Jie
    Gao, Zhitao
    Li, Xiang
    Dong, Liang
    Han, Weidong
    Nie, Jing
    ONCOTARGET, 2017, 8 (66) : 110693 - 110707
  • [12] Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?
    Konstantinidou, Markella
    Zarganes-Tzitzikas, Tryfon
    Magiera-Mularz, Katarzyna
    Holak, Tad A.
    Domling, Alexander
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2018, 57 (18) : 4840 - 4848
  • [13] Macrocyclic Peptide Inhibitor of PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Kuska, Katarzyna
    Skalniak, Lukasz
    Grudnik, Przemyslaw
    Musielak, Bogdan
    Plewka, Jacek
    Kocik, Justyna
    Stec, Malgorzata
    Weglarczyk, Kazimierz
    Sala, Dominik
    Wladyka, Benedykt
    Siedlar, Maciej
    Holak, Tad A.
    Dubin, Grzegorz
    ADVANCED THERAPEUTICS, 2021, 4 (02)
  • [14] Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Skalniak, Lukasz
    Zak, Krzysztof M.
    Musielak, Bogdan
    Rudzinska-Szostak, Ewa
    Berlicki, Lukasz
    Kocik, Justyna
    Grudnik, Przemyslaw
    Sala, Dominik
    Zarganes-Tzitzikas, Tryfon
    Shaabani, Shabnam
    Doemling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (44) : 13732 - 13735
  • [15] Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
    Hashimoto, Kazuhiko
    Nishimura, Shunji
    Akagi, Masao
    DIAGNOSTICS, 2020, 10 (08)
  • [16] Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
    Anand, Kartik
    Sahu, Geetanjali
    Burns, Ethan
    Ensor, Allyne
    Ensor, Joe
    Pingali, Sai Ravi
    Subbiah, Vivek
    Iyer, Swaminathan P.
    ESMO OPEN, 2020, 5 (04)
  • [17] Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
    Meng, Xiangjiao
    Huang, Zhaoqin
    Teng, Feifei
    Xing, Ligang
    Yu, Jinming
    CANCER TREATMENT REVIEWS, 2015, 41 (10) : 868 - 876
  • [18] Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
    Wu, Bogang
    Sun, Xiujie
    Gupta, Harshita B.
    Yuan, Bin
    Li, Jingwei
    Ge, Fei
    Chiang, Huai-Chin
    Zhang, Xiaowen
    Zhang, Chi
    Zhang, Deyi
    Yang, Jing
    Hu, Yanfen
    Curiel, Tyler J.
    Li, Rong
    ONCOIMMUNOLOGY, 2018, 7 (11):
  • [19] PD-1 and PD-L1 expression in rare lung tumors
    Gyulai, Marton
    Megyesfalvi, Zsolt
    Reiniger, Lilla
    Harko, Tunde
    Ferencz, Bence
    Karsko, Luca
    Agocs, Laszlo
    Fillinger, Janos
    Dome, Balazs
    Szallasi, Zoltan
    Moldvay, Judit
    PATHOLOGY & ONCOLOGY RESEARCH, 2023, 29
  • [20] The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
    Tang, Qing
    Chen, Yun
    Li, Xiaojuan
    Long, Shunqin
    Shi, Yao
    Yu, Yaya
    Wu, Wanyin
    Han, Ling
    Wang, Sumei
    FRONTIERS IN IMMUNOLOGY, 2022, 13